Advancing a platform of a novel drug class, redox-active metalloporphyrins, for the treatment of cancer patients.
BioMimetix, founded in 2013, is a pioneering small biotechnology firm at the forefront of transforming the landscape of cancer treatment with our novel compound, BMX-001. Leveraging groundbreaking research, we have developed a redox-active compound poised to revolutionize cancer treatment.
With a strategic focus on effective resource management, our company has demonstrated exceptional financial acumen over the past decade and completion of exciting Phase 2 data.
![ndc100px](https://biomimetixpharma.com/wp-content/uploads/2023/11/ndc100px.png)
New drug class preparing for Phase 3 pivotal trial in high-grade glioma
![dce100px](https://biomimetixpharma.com/wp-content/uploads/2023/11/dce100px.png)
Demonstrated clinical efficacy in multiple oncology indications
![pd100px](https://biomimetixpharma.com/wp-content/uploads/2023/11/pd100px.png)
Platform drug transforming chemoradiation in multiple cancers
![uda100px](https://biomimetixpharma.com/wp-content/uploads/2023/11/uda100px.png)
Unique dual action
enhances
tumor killing
and protects healthy tissue
![fbt100px](https://biomimetixpharma.com/wp-content/uploads/2023/11/fbt100px.png)